Pifeltro
Payments companies reported to CMS as associated with Pifeltro. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Pifeltro, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Pifeltro
These are the largest totals companies reported as associated with Pifeltro. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jihad Slim | Newark, NJ | Infectious Disease | $37,075.13 |
| Gary Sinclair | Dallas, TX | Internal Medicine | $22,081.07 |
| Ricky Hsu | New York, NY | Internal Medicine | $19,305.23 |
| Mohammed Reza | Jacksonville, FL | Infectious Disease | $19,163.47 |
| Michael Harbour | Stanford, CA | Infectious Disease | $16,971.94 |
| John Hogan | Washington, DC | Gastroenterology (Internal Medicine) | $16,206.78 |
| Douglas Cunningham | Phoenix, AZ | Family Medicine | $15,742.45 |
| Harish Moorjani | Briarcliff Manor, NY | Infectious Disease | $13,436.42 |
| Elie Helou | Waterbury, CT | Internal Medicine | $12,298.41 |
| Antonio Urbina | New York, NY | Infectious Disease | $12,244.79 |
Prescribed Pifeltro?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.